Drisapersen / DMD (SRPT, RNA)
Then finally on drisapersen for Duchenne Muscular Dystrophy, I note that Sarepta has now announced that it intends to file its similar product on the back of Phase II data in 2014. Is there any reason why GSK wasn’t able to file on Phase II or following this news, can you accelerate or augment your file?
As far as the Duchenne Muscular Dystrophy is concerned, the big difference is that we believe we shall have a package that is focused on clinical endpoints rather than surrogate markers: a different strategy and we like that strategy.
According to @ligand_LGND "GSK cites growth due to US contributions from new Hep C indication"
Total sales $70m, made up of US ($29), EU ($20m), ROW ($21m)